Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eco Animal Health GroupFRA:LWA -0.90%56 EV-to-EBITDA is 8.37 as of Aug. 05, 2026, which is 48% below its 10-year median of 16.21. GuruFocus rates FRA:LWA with a GF Score™ of 56/100 and a GF Value™ of €1.02. The stock has 3 warning signs investors should review. Among 745 Drug Manufacturers companies, Eco Animal Health Group ranks better than 69.8% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eco Animal Health Group's enterprise value is €82.0 Mil.
Eco Animal Health Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €9.8 Mil. Therefore, Eco Animal Health Group's EV-to-EBITDA for today is 8.37.
The historical rank and industry rank for Eco Animal Health Group's EV-to-EBITDA or its related term are showing as below:
FRA:LWA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.36 Med: 16.21 Max: 33.01
Current: 8.23
During the past 13 years, the highest EV-to-EBITDA of Eco Animal Health Group was 33.01. The lowest was 3.36. And the median was 16.21.
FRA:LWA's EV-to-EBITDA is ranked better than 69.8% of 745
companies
in the Drug Manufacturers industry
Industry Median: 13.04
vs FRA:LWA: 8.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Eco Animal Health Group (FRA:LWA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eco Animal Health Group's PE Ratio (TTM) for today is calculated as:
Eco Animal Health Group's share price for today is €1.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eco Animal Health Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.037.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LWA vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Eco Animal Health Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eco Animal Health Group EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eco Animal Health Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eco Animal Health Group's EV-to-EBITDA falls into.
Eco Animal Health Group's current Enterprise Value is €82.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eco Animal Health Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €9.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eco Animal Health Group (FRA:LWA) has a EV-to-EBITDA of 8.37 as of Aug. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eco Animal Health Group. This is 48% below median its historical median of 16.21. Over the past decade, Eco Animal Health Group's EV-to-EBITDA has ranged from 3.36 to 33.01. According to the industry distribution chart, Eco Animal Health Group ranks #225 out of 745 companies in the Drug Manufacturers industry, placing it in the top 30.2%.
Is Eco Animal Health Group's EV-to-EBITDA too high?
Eco Animal Health Group's current EV-to-EBITDA of 8.37 is 48% below median its 10-year median of 16.21. Over the past 10 years, this metric has ranged from a low of 3.36 to a high of 33.01. The Drug Manufacturers industry median EV-to-EBITDA is 13.04. Eco Animal Health Group's value of 8.37 is 35.8% below this industry median. Based on the distribution chart, Eco Animal Health Group ranks #225 out of 745 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Eco Animal Health Group has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Eco Animal Health Group's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eco Animal Health Group ranks #225 out of 745 companies for EV-to-EBITDA. This puts Eco Animal Health Group in the upper half of its industry. The industry median EV-to-EBITDA is 13.04. Eco Animal Health Group's value of 8.37 is 35.8% below this benchmark. Historically, Eco Animal Health Group's own EV-to-EBITDA has ranged from 3.36 to 33.01 over the past decade. While the company's 10-year median is 16.21 vs. the industry median of 13.04, Eco Animal Health Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.04, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eco Animal Health Group's current EV-to-EBITDA of 8.37 is 35.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eco Animal Health Group. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eco Animal Health Group's current EV-to-EBITDA is 8.37, which is 48% below median its own 10-year median of 16.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eco Animal Health Group stock overvalued right now?
Eco Animal Health Group (FRA:LWA) has a current EV-to-EBITDA of 8.37. The stock's GF Value™ is €1.02, compared to a current price of €1.10 — trading 7.8% above its estimated fair value. The current EV-to-EBITDA is 8.37, which is 48% below median its 10-year median of 16.21 and 35.8% below the Drug Manufacturers industry median of 13.04. Eco Animal Health Group's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Eco Animal Health Group (FRA:LWA), the current EV-to-EBITDA is 8.37 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eco Animal Health Group (FRA:LWA) Overvalued in 2026?
Based on GuruFocus' analysis, Eco Animal Health Group stock appears to be overvalued.
The current stock price of €1.10 is trading 7.8% above its estimated GF Value™ of €1.02.
Key valuation signals for FRA:LWA:
EV-to-EBITDA: 8.37 (48% below median its 10-year median of 16.21)
GF Value™: €1.02 vs. price of €1.10 (7.8% above fair value)
Industry Position: 35.8% below the Drug Manufacturers median (#225 of 745)
No single metric tells the full story. See the FRA:LWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eco Animal Health Group PLC is an animal health biotech company. It provides quality products for swine and poultry, anti-infectives to treat illness, improve health, and performance. Its products include Aivlosin/Valosin Solutions and Parasite Solutions. The company's segments include Corporate/UK, China and Japan, North America, South and Southeast Asia, Latin America, Europe, and the Rest of the World, with the majority of the revenue deriving from China and Japan.
56GF Score
Get the complete analysis for FRA:LWA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LWA has been successfully added to your 
